Abstract
Sir, Double-boosted protease inhibitor (DBPI) therapy has been an option in HIV-infected individuals requiring salvage therapy, including those who have exhausted treatment options, harbour complex resistance mutations or have intolerance to nucleoside reverse transcriptase inhibitors (NRTIs). Studies have shown a range of virological responses 1‐5 and in a retrospective clinical cohort comparing DBPI versus single PI regimens no significant differences in the relative odds of viral suppression were
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
